Home » Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results

Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results

by UroToday | Jul 5, 2024 | Articles | 0 Comments